...
search icon
cort-img

Corcept Therapeutics Incorporated Share Price

CORT
NAQ
$34.24
-$5.58
(-14.01%)
1D
Industry: Pharmaceuticals Sector: Health Care

Corcept Therapeutics Incorporated Analyst Forecast

Corcept Therapeutics Incorporated Share Price Chart

Corcept Therapeutics Incorporated Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$4.19B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
45.5517
Volume info-icon
This is the total number of shares traded during the most recent trading day.
11.76M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.26
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$32.99 L
$117.33 H
$34.24

About Corcept Therapeutics Incorporated, Common Stock

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California. more

Industry: PharmaceuticalsSector: Health Care

Corcept Therapeutics Incorporated Stock Returns

Time FrameCORTSectorS&P500
1-Week Return-10.69%1.07%0.74%
1-Month Return-2.98%1.46%1.28%
3-Month Return-55.01%3.51%3.6%
6-Month Return-51.22%15.29%7.31%
1-Year Return-53.43%7.7%11.97%
3-Year Return56.7%21.02%72.07%
5-Year Return27.1%37.81%76.01%
10-Year Return771.25%139.15%258.47%

Corcept Therapeutics Incorporated Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue353.87M365.98M401.86M482.38M675.04M[{"date":"2020-12-31","value":52.42,"profit":true},{"date":"2021-12-31","value":54.22,"profit":true},{"date":"2022-12-31","value":59.53,"profit":true},{"date":"2023-12-31","value":71.46,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue5.58M5.28M5.38M6.48M10.88M[{"date":"2020-12-31","value":51.3,"profit":true},{"date":"2021-12-31","value":48.53,"profit":true},{"date":"2022-12-31","value":49.49,"profit":true},{"date":"2023-12-31","value":59.56,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit348.29M360.70M396.47M475.89M664.16M[{"date":"2020-12-31","value":52.44,"profit":true},{"date":"2021-12-31","value":54.31,"profit":true},{"date":"2022-12-31","value":59.7,"profit":true},{"date":"2023-12-31","value":71.65,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin98.42%98.56%98.66%98.66%98.39%[{"date":"2020-12-31","value":99.76,"profit":true},{"date":"2021-12-31","value":99.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.72,"profit":true}]
Operating Expenses220.09M236.22M283.84M368.61M527.21M[{"date":"2020-12-31","value":41.75,"profit":true},{"date":"2021-12-31","value":44.81,"profit":true},{"date":"2022-12-31","value":53.84,"profit":true},{"date":"2023-12-31","value":69.92,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income128.20M124.48M112.63M107.28M136.95M[{"date":"2020-12-31","value":93.61,"profit":true},{"date":"2021-12-31","value":90.89,"profit":true},{"date":"2022-12-31","value":82.24,"profit":true},{"date":"2023-12-31","value":78.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense6.80M1.06M7.11M34.55M49.08M[{"date":"2020-12-31","value":13.85,"profit":true},{"date":"2021-12-31","value":2.16,"profit":true},{"date":"2022-12-31","value":14.49,"profit":true},{"date":"2023-12-31","value":70.39,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income131.60M125.01M116.19M124.56M161.49M[{"date":"2020-12-31","value":81.49,"profit":true},{"date":"2021-12-31","value":77.41,"profit":true},{"date":"2022-12-31","value":71.95,"profit":true},{"date":"2023-12-31","value":77.13,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes25.59M12.49M14.77M18.42M20.28M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":48.82,"profit":true},{"date":"2022-12-31","value":57.73,"profit":true},{"date":"2023-12-31","value":71.97,"profit":true},{"date":"2024-12-31","value":79.26,"profit":true}]
Income After Taxes106.01M112.51M101.42M106.14M141.21M[{"date":"2020-12-31","value":75.07,"profit":true},{"date":"2021-12-31","value":79.68,"profit":true},{"date":"2022-12-31","value":71.82,"profit":true},{"date":"2023-12-31","value":75.17,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations106.01M112.51M101.42M106.14M141.21M[{"date":"2020-12-31","value":75.07,"profit":true},{"date":"2021-12-31","value":79.68,"profit":true},{"date":"2022-12-31","value":71.82,"profit":true},{"date":"2023-12-31","value":75.17,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income106.01M112.51M101.42M106.14M139.73M[{"date":"2020-12-31","value":75.87,"profit":true},{"date":"2021-12-31","value":80.52,"profit":true},{"date":"2022-12-31","value":72.58,"profit":true},{"date":"2023-12-31","value":75.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)0.850.890.880.951.24[{"date":"2020-12-31","value":68.55,"profit":true},{"date":"2021-12-31","value":71.77,"profit":true},{"date":"2022-12-31","value":70.97,"profit":true},{"date":"2023-12-31","value":76.61,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]

Corcept Therapeutics Incorporated Ratios

Corcept Therapeutics Incorporated Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CORT
Cash Ratio 2.45
Current Ratio 3.14
Quick Ratio 3.07

Corcept Therapeutics Incorporated Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CORT
ROA (LTM) 5.10%
ROE (LTM) 16.70%

Corcept Therapeutics Incorporated Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CORT
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Corcept Therapeutics Incorporated Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CORT
Trailing PE 45.55
Forward PE 76.92
P/S (TTM) 5.63
P/B 6.65
Price/FCF 77
EV/R 5.11
EV/Ebitda 56.18
PEG 0.61

FAQs

What is Corcept Therapeutics Incorporated share price today?

Corcept Therapeutics Incorporated (CORT) share price today is $34.24

Can Indians buy Corcept Therapeutics Incorporated shares?

Yes, Indians can buy shares of Corcept Therapeutics Incorporated (CORT) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CORT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Corcept Therapeutics Incorporated be purchased?

Yes, you can purchase fractional shares of Corcept Therapeutics Incorporated (CORT) via the Vested app. You can start investing in Corcept Therapeutics Incorporated (CORT) with a minimum investment of $1.

How to invest in Corcept Therapeutics Incorporated shares from India?

You can invest in shares of Corcept Therapeutics Incorporated (CORT) via Vested in three simple steps:

  • Click on Sign Up or Invest in CORT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Corcept Therapeutics Incorporated shares
What is Corcept Therapeutics Incorporated 52-week high and low stock price?

The 52-week high price of Corcept Therapeutics Incorporated (CORT) is $117.33. The 52-week low price of Corcept Therapeutics Incorporated (CORT) is $32.99.

What is Corcept Therapeutics Incorporated price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Corcept Therapeutics Incorporated (CORT) is 45.5517

What is Corcept Therapeutics Incorporated price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Corcept Therapeutics Incorporated (CORT) is 6.65

What is Corcept Therapeutics Incorporated dividend yield?

The dividend yield of Corcept Therapeutics Incorporated (CORT) is 0.00%

What is the Market Cap of Corcept Therapeutics Incorporated?

The market capitalization of Corcept Therapeutics Incorporated (CORT) is $4.19B

What is Corcept Therapeutics Incorporated's stock symbol?

The stock symbol (or ticker) of Corcept Therapeutics Incorporated is CORT

How Can Investors Use Corcept Therapeutics Incorporated Share Price Data for Long-Term Investment Decisions?

Consider the share price of Corcept Therapeutics Incorporated as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Corcept Therapeutics Incorporated has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Corcept Therapeutics Incorporated shares for Indian investors?

When investing in Corcept Therapeutics Incorporated shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Corcept Therapeutics Incorporated stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Corcept Therapeutics Incorporated share price with other stocks in the same sector?

Rather than merely checking the share price of Corcept Therapeutics Incorporated and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Corcept Therapeutics Incorporated stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top